Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia

Trial Profile

Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2011

At a glance

  • Drugs Doxepin (Primary)
  • Indications Insomnia
  • Focus Registrational; Therapeutic Use
  • Sponsors Somaxon Pharmaceuticals
  • Most Recent Events

    • 20 May 2009 Results presented at the 162nd Annual Meeting of the American Psychiatric Association (APA 2009).
    • 11 Jun 2008 New trial record.
    • 07 May 2008 Results data have been reported in a Somaxon media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top